Literature DB >> 28258217

Heterodimers of serotonin receptor subtypes 2 are driven by 5-HT2C protomers.

Imane Moutkine1,2,3, Emily Quentin1,2,3, Bruno P Guiard4, Luc Maroteaux5,2,3, Stephane Doly6,7,8.   

Abstract

The serotonin receptor subtypes 2 comprise 5-HT2A, 5-HT2B, and 5-HT2C, which are Gαq-coupled receptors and display distinct pharmacological properties. Although co-expressed in some brain regions and involved in various neurological disorders, their functional interactions have not yet been studied. We report that 5-HT2 receptors can form homo- and heterodimers when expressed alone or co-expressed in transfected cells. Co-immunoprecipitation and bioluminescence resonance energy transfer studies confirmed that 5-HT2C receptors interact with either 5-HT2A or 5-HT2B receptors. Although heterodimerization with 5-HT2C receptors does not alter 5-HT2C Gαq-dependent inositol phosphate signaling, 5-HT2A or 5-HT2B receptor-mediated signaling was totally blunted. This feature can be explained by a dominance of 5-HT2C on 5-HT2A and 5-HT2B receptor binding; in 5-HT2C-containing heterodimers, ligands bind and activate the 5-HT2C protomer exclusively. This dominant effect on the associated protomer was also observed in neurons, supporting the physiological relevance of 5-HT2 receptor heterodimerization in vivo Accordingly, exogenous expression of an inactive form of the 5-HT2C receptor in the locus ceruleus is associated with decreased 5-HT2A-dependent noradrenergic transmission. These data demonstrate that 5-HT2 receptors can form functionally asymmetric heterodimers in vitro and in vivo that must be considered when analyzing the physiological or pathophysiological roles of serotonin in tissues where 5-HT2 receptors are co-expressed.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  G protein-coupled receptor (GPCR); cell signaling; cell-surface receptor; dimerization; molecular pharmacology; receptor regulation; serotonin; signal transduction

Mesh:

Substances:

Year:  2017        PMID: 28258217      PMCID: PMC5391763          DOI: 10.1074/jbc.M117.779041

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  The angiotensin II AT2 receptor is an AT1 receptor antagonist.

Authors:  S AbdAlla; H Lother; A M Abdel-tawab; U Quitterer
Journal:  J Biol Chem       Date:  2001-08-15       Impact factor: 5.157

2.  Control of 5-hydroxytryptamine release in the dorsal raphe nucleus by the noradrenergic system in rat brain. Role of alpha-adrenoceptors.

Authors:  A Bortolozzi; F Artigas
Journal:  Neuropsychopharmacology       Date:  2002-07-19       Impact factor: 7.853

3.  Fluorescence studies of homooligomerization of adenosine A2A and serotonin 5-HT1A receptors reveal the specificity of receptor interactions in the plasma membrane.

Authors:  Sylwia Łukasiewicz; Ewa Błasiak; Agata Faron-Górecka; Agnieszka Polit; Magsalena Tworzydło; Andrzej Górecki; Zygmunt Wasylewski; Marta Dziedzicka-Wasylewska
Journal:  Pharmacol Rep       Date:  2007 Jul-Aug       Impact factor: 3.024

4.  G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient.

Authors:  Lucie P Pellissier; Gaël Barthet; Florence Gaven; Elisabeth Cassier; Eric Trinquet; Jean-Philippe Pin; Philippe Marin; Aline Dumuis; Joël Bockaert; Jean-Louis Banères; Sylvie Claeysen
Journal:  J Biol Chem       Date:  2011-01-19       Impact factor: 5.157

5.  5-HT₂A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system.

Authors:  G Quesseveur; C Repérant; D J David; A M Gardier; C Sanchez; B P Guiard
Journal:  Exp Brain Res       Date:  2013-02-15       Impact factor: 1.972

6.  The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition.

Authors:  K Siddiquee; J Hampton; D McAnally; Lt May; Lh Smith
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 7.  Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions.

Authors:  Mark J Millan; Philippe Marin; Joëel Bockaert; Clotilde Mannoury la Cour
Journal:  Trends Pharmacol Sci       Date:  2008-09       Impact factor: 14.819

8.  Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum.

Authors:  R P Ward; D M Dorsa
Journal:  J Comp Neurol       Date:  1996-07-01       Impact factor: 3.215

9.  Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons.

Authors:  Steven T Szabo; Pierre Blier
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

10.  μ-Opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways.

Authors:  Didier Cussac; Isabelle Rauly-Lestienne; Peter Heusler; Frédéric Finana; Claudie Cathala; Sophie Bernois; Luc De Vries
Journal:  Cell Signal       Date:  2012-04-25       Impact factor: 4.315

View more
  13 in total

1.  Coevolution of Residues Provides Evidence of a Functional Heterodimer of 5-HT2AR and 5-HT2CR Involving Both Intracellular and Extracellular Domains.

Authors:  Bernard Fongang; Kathryn A Cunningham; Maga Rowicka; Andrzej Kudlicki
Journal:  Neuroscience       Date:  2019-06-01       Impact factor: 3.590

2.  Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

Authors:  Clinton E Canal
Journal:  Handb Exp Pharmacol       Date:  2018

3.  Cervical spinal 5-HT2A and 5-HT2B receptors are both necessary for moderate acute intermittent hypoxia-induced phrenic long-term facilitation.

Authors:  Arash Tadjalli; Gordon S Mitchell
Journal:  J Appl Physiol (1985)       Date:  2019-06-20

Review 4.  Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders.

Authors:  Miguel Pérez de la Mora; Dasiel O Borroto-Escuela; Minerva Crespo-Ramírez; José Del Carmen Rejón-Orantes; Daniel Alejandro Palacios-Lagunas; Magda K Martínez-Mata; Daniela Sánchez-Luna; Emiliano Tesoro-Cruz; Kjell Fuxe
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

5.  Endogenous Serotonin 5-HT2A and 5-HT2C Receptors Associate in the Medial Prefrontal Cortex.

Authors:  Amanda E Price; Dennis J Sholler; Sonja J Stutz; Noelle C Anastasio; Kathryn A Cunningham
Journal:  ACS Chem Neurosci       Date:  2019-03-18       Impact factor: 4.418

6.  Preferential modulation of the lateral habenula activity by serotonin-2A rather than -2C receptors: Electrophysiological and neuroanatomical evidence.

Authors:  Francis Delicata; Cristiano Bombardi; Massimo Pierucci; Roberto Di Maio; Philippe De Deurwaerdère; Giuseppe Di Giovanni
Journal:  CNS Neurosci Ther       Date:  2018-02-25       Impact factor: 5.243

Review 7.  Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.

Authors:  David E Olson
Journal:  Biochemistry       Date:  2022-01-21       Impact factor: 3.162

8.  Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway.

Authors:  Mark B Zimering
Journal:  J Endocrinol Diabetes       Date:  2017-10-04

9.  Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.

Authors:  Noelle C Anastasio; Dennis J Sholler; Robert G Fox; Sonja J Stutz; Christina R Merritt; James M Bjork; F Gerard Moeller; Kathryn A Cunningham
Journal:  Neuropharmacology       Date:  2020-02-14       Impact factor: 5.250

10.  Longer trinucleotide repeats of androgen receptor are associated with higher testosterone and low oxytocin levels in diabetic premature ejaculatory dysfunction patients.

Authors:  Haroon Latif Khan; Shahzad Bhatti; Sana Abbas; Yousaf Latif Khan; Rosa Maria Marquez Gonzalez; Muhammad Aslamkhan; Gerardo Rodriguez Gonzalez; Hikmet Hakan Aydin
Journal:  Basic Clin Androl       Date:  2018-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.